Switch from entecavir to tenofovir for chronic hepatitis B
Treatments studied
Part of Infections clinical trials.
This trial studies switching people with chronic hepatitis B from entecavir (ETV) to tenofovir alafenamide (TAF). It may help if you feel your current entecavir treatment isn’t working well enough or is inconvenient.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 20 years old
- Your blood test shows active hepatitis B (HBsAg is detectable)
- You have chronic hepatitis B and are currently taking entecavir (ETV)
- You feel your entecavir treatment is not effective enough or is inconvenient
- You have no known medical reason you can’t safely take tenofovir (TAF)
- You expect to be able to stay on hepatitis B antiviral treatment for at least 1 more year
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares two approved hepatitis B medicines—tenofovir alafenamide and entecavir—to see which works best for people with chronic hepatitis B. It may help improve control of the virus and support better long-term liver health.
This study tests if switching your current hepatitis B antiviral to Tenofovir Alafenamide (TAF) keeps your new liver working well with fewer side effects. It is for people who had a liver transplant due to hepatitis B and have stable liver function for at least a year.
This trial tests if taking tenofovir alafenamide (TAF) alone works as well as combining it with entecavir (ETV) to improve outcomes for people with hepatitis B and liver cancer who are receiving immunotherapy.
This trial tests tenofovir alafenamide (a hepatitis B antiviral medicine) to see if it can prevent liver disease from getting worse in people with chronic hepatitis B who currently have stable (normal) liver blood tests and low virus levels. It may help lower the chance of developing serious liver complications over time.
This trial studies what happens after stopping long-term hepatitis B antiviral medicine in people whose virus has stayed controlled. It also follows patients over time to see how well they remain stable and safe after stopping.
This trial tests switching from standard entecavir pills to a different form (ODT, which dissolves in your mouth) for people who have had a stable liver transplant for hepatitis B. It aims to see if the new form works just as well and is safe.
Hear when a new Patient Satisfaction trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.